Detalhe da pesquisa
1.
Acidity changes immunology: a new VISTA pathway.
Nat Immunol
; 21(1): 13-16, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31822869
2.
VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.
Trends Immunol
; 42(3): 209-227, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33495077
3.
Regulation of HHLA2 expression in kidney cancer and myeloid cells.
BMC Cancer
; 23(1): 1039, 2023 Oct 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37891555
4.
Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model.
Haematologica
; 106(5): 1330-1342, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33538148
5.
A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression.
Cancer Immunol Immunother
; 68(3): 421-432, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30564891
6.
Prognostic and predictive markers for the new immunotherapies.
Oncology (Williston Park)
; 28 Suppl 3: 39-48, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25384886
7.
Phase 1 first-in-human study of dalutrafusp alfa, an anti-CD73-TGF-ß-trap bifunctional antibody, in patients with advanced solid tumors.
J Immunother Cancer
; 11(2)2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36746510
8.
Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights.
Front Oncol
; 13: 1225081, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37795437
9.
Soluble PD-L1 as an early marker of progressive disease on nivolumab.
J Immunother Cancer
; 10(2)2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35131863
10.
Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
Cancer
; 117(24): 5461-8, 2011 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21681735
11.
Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses.
Cancer Immunol Res
; 9(12): 1465-1475, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34635486
12.
KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1.
Cancer Immunol Res
; 9(2): 156-169, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33229411
13.
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma.
Cancer Cell
; 39(5): 632-648.e8, 2021 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33711273
14.
The importance of exosomal PDL1 in tumour immune evasion.
Nat Rev Immunol
; 20(4): 209-215, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31965064
15.
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
Clin Cancer Res
; 25(7): 2174-2184, 2019 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30670497
16.
CD13/APN transcription is regulated by the proto-oncogene c-Maf via an atypical response element.
Gene
; 403(1-2): 178-87, 2007 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17897790
17.
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Cancer Immunol Res
; 5(6): 480-492, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28522460
18.
Learning from PD-1 Resistance: New Combination Strategies.
Trends Mol Med
; 22(6): 448-451, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27174038
19.
Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.
Clin Genitourin Cancer
; 14(4): 304-313.e6, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27036973
20.
Combination cancer immunotherapy and new immunomodulatory targets.
Nat Rev Drug Discov
; 14(8): 561-84, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26228759